125 related articles for article (PubMed ID: 16459257)
41. Uptake and washout of I-123-MIBG in neuronal and non-neuronal sites in rat hearts: relationship to renal clearance.
Arbab AS; Koizumi K; Araki T
Ann Nucl Med; 1996 May; 10(2):211-7. PubMed ID: 8800450
[TBL] [Abstract][Full Text] [Related]
42. Comparative effects of 1-ethyl- and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridines on catecholamine concentrations in mouse brain and heart.
Fuller RW; Hemrick-Luecke SK; Robertson DW
Res Commun Chem Pathol Pharmacol; 1988 Jan; 59(1):129-32. PubMed ID: 3258433
[TBL] [Abstract][Full Text] [Related]
43. Normal
Amino M; Yoshioka K; Tanaka S; Kawabe N; Kurosawa H; Uchida K; Oshikiri S; Hashida T; Kanda S; Inokuchi S; Ikari Y
Pacing Clin Electrophysiol; 2017 Oct; 40(10):1103-1112. PubMed ID: 28857212
[TBL] [Abstract][Full Text] [Related]
44. Loss of 123I-MIBG uptake by the heart in Parkinson's disease: assessment of cardiac sympathetic denervation and diagnostic value.
Ohmura M
J Nucl Med; 2000 Sep; 41(9):1594-5. PubMed ID: 10994743
[No Abstract] [Full Text] [Related]
45. Radiolabeled phenethylguanidines: novel imaging agents for cardiac sympathetic neurons and adrenergic tumors.
Raffel DM; Jung YW; Gildersleeve DL; Sherman PS; Moskwa JJ; Tluczek LJ; Chen W
J Med Chem; 2007 May; 50(9):2078-88. PubMed ID: 17419605
[TBL] [Abstract][Full Text] [Related]
46. A 99mTc(CO)3 -labeled benzylguanidine with persistent heart uptake.
Oliveira BL; Morais M; Gano L; Santos I; Correia JD
J Labelled Comp Radiopharm; 2014 May; 57(5):358-64. PubMed ID: 24861983
[TBL] [Abstract][Full Text] [Related]
47. Cardiac retention of PET neuronal imaging agent LMI1195 in different species: impact of norepinephrine uptake-1 and -2 transporters.
Yu M; Bozek J; Kagan M; Guaraldi M; Silva P; Azure M; Onthank D; Robinson SP
Nucl Med Biol; 2013 Jul; 40(5):682-8. PubMed ID: 23601914
[TBL] [Abstract][Full Text] [Related]
48. Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains.
Haobam R; Sindhu KM; Chandra G; Mohanakumar KP
Behav Brain Res; 2005 Sep; 163(2):159-67. PubMed ID: 15941598
[TBL] [Abstract][Full Text] [Related]
49. Dexmedetomidine does not interfere with meta-iodobenzylguanidine (MIBG) uptake at clinically relevant concentrations.
Batra V; Makvandi M; Zuppa AF; Patel N; Elias J; Pryma DA; Maris JM
Pediatr Blood Cancer; 2017 Apr; 64(4):. PubMed ID: 27654664
[TBL] [Abstract][Full Text] [Related]
50. Intervention with exercise restores motor deficits but not nigrostriatal loss in a progressive MPTP mouse model of Parkinson's disease.
Sconce MD; Churchill MJ; Greene RE; Meshul CK
Neuroscience; 2015 Jul; 299():156-74. PubMed ID: 25943481
[TBL] [Abstract][Full Text] [Related]
51. Comparison of high-specific-activity ultratrace 123/131I-MIBG and carrier-added 123/131I-MIBG on efficacy, pharmacokinetics, and tissue distribution.
Barrett JA; Joyal JL; Hillier SM; Maresca KP; Femia FJ; Kronauge JF; Boyd M; Mairs RJ; Babich JW
Cancer Biother Radiopharm; 2010 Jun; 25(3):299-308. PubMed ID: 20578835
[TBL] [Abstract][Full Text] [Related]
52. Ameliorating effect of dimethylsulfoniopropionate on the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease of mice.
Nakajima K; Minematsu M
J Nutr Sci Vitaminol (Tokyo); 2006 Feb; 52(1):70-4. PubMed ID: 16637233
[TBL] [Abstract][Full Text] [Related]
53. Clinical use of metaiodobenzylguanidine imaging in cardiology.
Merlet P; Piot O; Dubois-Randé JL; Loisance D; Castaigne A; Syrota A
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):29-39. PubMed ID: 9002746
[TBL] [Abstract][Full Text] [Related]
54. Synthesis and evaluation of
Das S; Sakhare N; Mathur A; Mallia MB; Mirapurkar S; Sheela M; Sarma HD; Sachdev SS; Dash A
Nucl Med Biol; 2019; 68-69():49-57. PubMed ID: 30770228
[TBL] [Abstract][Full Text] [Related]
55. Effect of oestrogen receptors on brain NMDA receptors of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice.
Al-Sweidi S; Morissette M; Di Paolo T
J Neuroendocrinol; 2012 Nov; 24(11):1375-85. PubMed ID: 22672467
[TBL] [Abstract][Full Text] [Related]
56. Relative uptake, metabolism, and beta-receptor binding of (1R,2S)-4-(18)F-fluorometaraminol and (123)I-MIBG in normotensive and spontaneously hypertensive rats.
Pissarek M; Ermert J; Oesterreich G; Bier D; Coenen HH
J Nucl Med; 2002 Mar; 43(3):366-73. PubMed ID: 11884497
[TBL] [Abstract][Full Text] [Related]
57. 2'-NH(2)-MPTP [1-methyl-4-(2'-aminophenyl)-1,2,3,6-tetrahydropyridine] depletes serotonin and norepinephrine in rats: a comparison with 2'-CH(3)-MPTP [1-methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine].
Unger EL; Mazzola-Pomietto P; Murphy DL; Andrews AM
J Pharmacol Exp Ther; 2002 Nov; 303(2):527-33. PubMed ID: 12388632
[TBL] [Abstract][Full Text] [Related]
58. Differentiation of dementia with Lewy bodies, Alzheimer's disease and vascular dementia by cardiac 131I-meta-iodobenzylguanidine (MIBG) uptake (preliminary report).
Jindahra P; Vejjajiva A; Witoonpanich R; Sirisriro R; Sritara C; Pulkes T
J Med Assoc Thai; 2004 Oct; 87(10):1176-81. PubMed ID: 15560694
[TBL] [Abstract][Full Text] [Related]
59. In vivo modulation of the Parkinsonian phenotype by Nrf2.
Burton NC; Kensler TW; Guilarte TR
Neurotoxicology; 2006 Dec; 27(6):1094-100. PubMed ID: 16959318
[TBL] [Abstract][Full Text] [Related]
60. Changes in cardiac sympathetic nerve innervation and activity in pathophysiologic transition from typical to end-stage hypertrophic cardiomyopathy.
Terai H; Shimizu M; Ino H; Yamaguchi M; Uchiyama K; Oe K; Nakajima K; Taki J; Kawano M; Mabuchi H
J Nucl Med; 2003 Oct; 44(10):1612-7. PubMed ID: 14530475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
